Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

This study has been terminated.
(Slow accrual)
Sigma Tau Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: May 23, 2013
Last updated: August 7, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2018
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)